Clostridioides difficile vegetative cells (C. difficile vegetative cells)

Clostridioides difficile vegetative cells are the metabolically active, toxin-producing form of the Gram-positive, anaerobic bacterium responsible for C. difficile infection (CDI) (StatPearls, 2023). Unlike the dormant spores, vegetative cells colonize the human colon following the disruption of normal gut microbiota, typically by broad-spectrum antibiotics (CDC, 2022). These cells produce two primary exotoxins, TcdA and TcdB, which cause mucosal inflammation, epithelial damage, and the characteristic symptoms of diarrhea and colitis (Nature Reviews Disease Primers, 2016). Therapeutic strategies primarily focus on killing these vegetative cells using antibiotics like vancomycin or fidaxomicin, or neutralizing their toxins (NIH, 2021). A major challenge in treatment is the persistence of spores, which are resistant to antibiotics and can germinate back into vegetative cells, leading to high rates of disease recurrence (Journal of Clinical Microbiology, 2018).

Other names

Clostridium difficile vegetative cellsC. difficileC. diffCDF

Antibiotics target vegetative cells through various pathways: vancomycin inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of nascent peptidoglycan (PubChem, 2024); fidaxomicin inhibits the bacterial RNA polymerase (FDA, 2011); and metronidazole causes DNA strand breakage via reactive intermediates (StatPearls, 2023). Bezlotoxumab is a monoclonal antibody that binds and neutralizes Toxin B produced by these cells (NIH, 2021).